Skip to main content

Table 4 Medication use at enrollment; PSOLAR psoriasis patients

From: Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

  Psoriasis patients self-reporting PsA, established by a HCPa (N = 1719) Psoriasis patients self-reporting PsAb (N = 4315) Patients with psoriasis onlyc (N = 7775) All PSOLAR patientsd (N = 12,090)
Patients with data, N 1714 4306 7762 12,068
Systemic steroids 566 (33.0)* 1284 (29.8)* 1548 (19.9) 2832 (23.5)
Retinoids and/or combination topical 760 (44.3) 2001 (46.5)* 3285 (42.3) 5286 (43.8)
 Taclonex 367 (21.4) 1146 (26.6) 1804 (23.2) 2950 (24.4)
 Acitretin 406 (23.7) 921 (21.4) 1506 (19.4) 2427 (20.1)
 Tazorac 164 (9.6) 561 (13.0) 758 (9.8) 1319 (10.9)
 Etretinate 25 (1.5) 50 (1.2) 53 (0.7) 103 (0.9)
Patients with NSAID data, N 1718 4310 7769 12,079
 NSAIDs 835 (48.6)* 1702 (39.5)* 540 (7.0) 2242 (18.6)
 Sulfasalazine 112 (6.5) 162 (3.8) 26 (0.3) 188 (1.6)
 Other NSAIDs 781 (45.5) 1626 (37.7) 520 (6.7) 2146 (17.8)
Immunomodulators 1193 (69.6)* 2567 (59.6)* 3221 (41.5) 5788 (48.0)
 Methotrexate 1104 (64.4) 2326 (54.0) 2634 (33.9) 4960 (41.1)
 Cyclosporine 339 (19.8) 738 (17.1) 1161 (15.0) 1899 (15.7)
 Oral Tacrolimus 1 (0.1) 3 (0.1) 4 (0.1) 7 (0.1)
 Mycophenolate mofetil 10 (0.6) 25 (0.6) 22 (0.3) 47 (0.4)
 Other Immunomodulators 60 (3.5) 131 (3.0) 147 (1.9) 278 (2.3)
Any biologic medications 1464 (85.2)* 3603 (83.5)* 5164 (66.4) 8767 (72.5)
History of biologic medications at entry
 Etanercept 893 (51.9) 2305 (53.4) 2581 (33.2) 4886 (40.4)
 Adalimumab 678 (39.4) 1673 (38.8) 1890 (24.3) 3563 (29.5)
 Infliximab 477 (27.7) 1037 (24.0) 895 (11.5) 1932 (16.0)
 Ustekinumab 378 (22.0) 703 (16.3) 1569 (20.2) 2272 (18.8)
 Efalizumab 147 (8.6) 452 (10.5) 892 (11.5) 1344 (11.1)
 Alefacept 96 (5.6) 272 (6.3) 428 (5.5) 700 (5.8)
 Golimumab 32 (1.9) 44 (1.0) 2 (0.0) 46 (0.4)
 Other 48 (2.8) 87 (2.0) 147 (1.9) 234 (1.9)
Number of biologic medications used prior to entry
 0 255 (14.8)* 712 (16.5)* 2611 (33.6) 3323 (27.5)
 1 682 (39.7) 1734 (40.2) 2992 (38.5) 4726 (39.1)
 2 445 (25.9) 1097 (25.4) 1366 (17.6) 2463 (20.4)
 3 222 (12.9) 525 (12.2) 592 (7.6) 1117 (9.2)
  ≥ 4 115 (6.7) 247 (5.7) 214 (2.8) 461 (3.8)
Topical therapy 1668 (97.3) 4207 (97.7)* 7485 (96.4) 11,692 (96.9)
 Topical steroid therapy 1637 (95.5) 4142 (96.2) 7325 (94.4) 11,467 (95.0)
 High potency 1373 (80.1) 3607 (83.8) 6156 (79.3) 9763 (80.9)
 Medium potency 1049 (61.2) 2680 (62.2) 4481 (57.7) 7161 (59.3)
 Low potency 707 (41.2) 1826 (42.4) 2749 (35.4) 4575 (37.9)
Phototherapy 1028 (60.0)* 2411 (56.0)ns 4172 (53.7) 6583 (54.5)
 Psoralens + UVA 417 (24.3) 860 (20.0) 1207 (15.6) 2067 (17.1)
 UVB 833 (48.6) 2000 (46.4) 3524 (45.4) 5524 (45.8)
 Laser 29 (1.7) 56 (1.3) 129 (1.7) 185 (1.5)
  1. Values are n (%)
  2. HCP healthcare provider, NSAID nonsteroidal anti-inflammatory drug, ns not significant, PsA psoriatic arthritis, UVA/UVB ultraviolet A/B
  3. *p < 0.001 vs. patients with psoriasis only
  4. ns indicates non-significant for psoriasis patients self-reporting PsA vs. patients with psoriasis only
  5. P-values for categorical variables were obtained from Pearson chi-square test with patients with psoriasis only as a reference
  6. aA subset of PSOLAR psoriasis patients self-reporting PsA, established by a HCP
  7. bPSOLAR psoriasis patients with self-reported PsA
  8. cPSOLAR psoriasis patients not self-reporting PsA
  9. dIncludes all PSOLAR patients with psoriasis who may or may not have PsA